Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DZD6008
- Development stage
- Phase 2
- Lead developer
- Dizal Pharmaceutical
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
DZD6008 is a novel, highly selective, brain-penetrant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) developed by Dizal Pharmaceutical as a potential treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations. It is designed to overcome resistance to existing EGFR TKIs and address the high incidence of brain metastases in this patient population. The drug acts by selectively inhibiting the activity of mutant EGFR, thereby blocking downstream signaling pathways that drive tumor growth and survival. Clinical trials are currently evaluating its safety and antitumor efficacy in patients who have progressed on prior therapies.
- Other names
- DZD-6008DZD6008DZD 6008
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on DZD6008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DZD6008.